Skip to main content

21.02.2024 | REVIEW

Onco-Pulmonology: Exploring a New Frontier in Pulmonary Medicine

verfasst von: Isaac Laniado, Antonio Velez, Daniel H. Sterman

Erschienen in: Current Pulmonology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To detail the proposed skills and roles of an onco-pulmonologist.

Recent Findings

Lung cancer remains the leading cause of cancer-related death in the USA, and it requires a comprehensive multidisciplinary approach to care, which can be affected in some cases by an imbalance of patients and available providers. While pulmonologists traditionally have played an important role in screening, prevention, diagnosis, and palliation of symptoms, training in onco-pulmonology has been proposed to help bridge the gaps in lung cancer care.

Summary

The onco-pulmonologist should be well versed in advanced diagnostic bronchoscopy and pleural procedures. Additionally, the onco-pulmonologist should have an in-depth knowledge of primary cancer therapies for thoracic malignancies and should be able to recognize and treat all common treatment-related toxicities. Ultimately, the onco-pulmonologist may serve in leadership roles at cancer centers including dedicated lung cancer screening programs and lung nodule surveillance.
Literatur
2.
Zurück zum Zitat Zhao X, Wen X, Wei W, Chen Y, Zhu J, Wang C. Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors. Oncotarget. 2017;8(28):46491–7.CrossRefPubMedPubMedCentral Zhao X, Wen X, Wei W, Chen Y, Zhu J, Wang C. Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors. Oncotarget. 2017;8(28):46491–7.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Gaga M, Powell CA, Schraufnagel DE, Schönfeld N, Rabe K, Hill NS, Sculier JP. ATS/ERS task force on the role of the pulmonologist in the management of lung cancer. An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med. 2013;188(4):503–7. https://doi.org/10.1164/rccm.201307-1269ST. Gaga M, Powell CA, Schraufnagel DE, Schönfeld N, Rabe K, Hill NS, Sculier JP. ATS/ERS task force on the role of the pulmonologist in the management of lung cancer. An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med. 2013;188(4):503–7. https://​doi.​org/​10.​1164/​rccm.​201307-1269ST.
5.
Zurück zum Zitat • Tandon S, Biraris P, Bhaskar M. ‘Pulmonary oncologist—an idea whose time has come?’, Indian J Med Paediatr Oncol. 2022;43(01):095–096. https://doi.org/10.1055/s-0042-1742638. Authors in this study highlight the need for a multidisciplinary approach to lung cancer care, especially in settings with significant shortage of medical oncologists. Training in pulmonary oncology is proposed to increase patient outreach and help close the gaps in care. • Tandon S, Biraris P, Bhaskar M. ‘Pulmonary oncologist—an idea whose time has come?’, Indian J Med Paediatr Oncol. 2022;43(01):095–096. https://​doi.​org/​10.​1055/​s-0042-1742638Authors in this study highlight the need for a multidisciplinary approach to lung cancer care, especially in settings with significant shortage of medical oncologists. Training in pulmonary oncology is proposed to increase patient outreach and help close the gaps in care.
6.
Zurück zum Zitat •• Tandon S, Biraris P, Bhaskar M. Pulmonary oncology-scope of the pulmonologist. Indian J Med Paediatr Oncol. 2022;43:29–33. https://doi.org/10.1055/s-0042-1742653. Authors in this study propose a set of skills that help define the role of a pulmonary oncologist. These remarks are based on the authors’ experience from a first of its kind 2-year training program in pulmonary oncology at their institution. •• Tandon S, Biraris P, Bhaskar M. Pulmonary oncology-scope of the pulmonologist. Indian J Med Paediatr Oncol. 2022;43:29–33. https://​doi.​org/​10.​1055/​s-0042-1742653Authors in this study propose a set of skills that help define the role of a pulmonary oncologist. These remarks are based on the authors’ experience from a first of its kind 2-year training program in pulmonary oncology at their institution.
9.
Zurück zum Zitat National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395–409. https://doi.org/10.1056/NEJMoa1102873. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395–409. https://​doi.​org/​10.​1056/​NEJMoa1102873.
10.
Zurück zum Zitat Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-effectiveness analysis of lung cancer screening in the United States: a comparative modeling study. Ann Intern Med. 2019;171(11):796–804. https://doi.org/10.7326/M19-0322.CrossRefPubMed Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-effectiveness analysis of lung cancer screening in the United States: a comparative modeling study. Ann Intern Med. 2019;171(11):796–804. https://​doi.​org/​10.​7326/​M19-0322.CrossRefPubMed
11.
Zurück zum Zitat • Smith HB, Ward R, Frazier C, Angotti J, Tanner NT. Guideline-recommended lung cancer screening adherence is superior with a centralized approach. Chest. 2022;161(3):818–825. https://doi.org/10.1016/j.chest.2021.09.002. Findings from this study highlight the improved screening ability and increased adherence to lung cancer screening programs with a centralized approach. • Smith HB, Ward R, Frazier C, Angotti J, Tanner NT. Guideline-recommended lung cancer screening adherence is superior with a centralized approach. Chest. 2022;161(3):818–825. https://​doi.​org/​10.​1016/​j.​chest.​2021.​09.​002. Findings from this study highlight the improved screening ability and increased adherence to lung cancer screening programs with a centralized approach.
19.
Zurück zum Zitat Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6(12):1952–6. https://doi.org/10.1001/jamaoncol.2020.5012.CrossRefPubMed Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6(12):1952–6. https://​doi.​org/​10.​1001/​jamaoncol.​2020.​5012.CrossRefPubMed
Metadaten
Titel
Onco-Pulmonology: Exploring a New Frontier in Pulmonary Medicine
verfasst von
Isaac Laniado
Antonio Velez
Daniel H. Sterman
Publikationsdatum
21.02.2024
Verlag
Springer US
Erschienen in
Current Pulmonology Reports
Elektronische ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-024-00342-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.